Physician profile
Gabriel Jacob
NPI 1316108038
$10,295.51
in general payments reported to CMS, 2019-2025
31 companies · $1,654 in 2025
The $1,654 reported for 2025 was more than what 86% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $998 · 2020: $711 · 2021: $1,047 · 2022: $1,136 · 2023: $1,666 · 2024: $3,084 · 2025: $1,654.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,297 · Long Term Medical Supply Or Device Loan: $1,107.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,296.90 |
| Long Term Medical Supply Or Device Loan | $1,106.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $3,310.14 | 2019-2025 | Luxor, Clareon, Rocklatan |
| Novartis Pharmaceuticals Corporation | $1,052.03 | 2019-2023 | |
| New World Medical,INC. | $614.20 | 2021-2025 | Streamline, Clearpath, Via360 |
| Genentech USA, INC. | $585.54 | 2019-2025 | Vabysmo |
| Sun Pharmaceutical Industries INC. | $573.96 | 2019-2024 | Cequa |
| Abbvie INC. | $493.35 | 2022-2025 | |
| Rxsight INC | $493.22 | 2022-2025 | Rxsight Injector Cartridge, Rxsight Contact Lens, Rxsight Light Delivery Device (Ldd) |
| Allergan, INC. | $415.01 | 2019-2022 | |
| Aerie Pharmaceuticals, INC. | $403.09 | 2019-2021 | |
| Glaukos Corporation | $291.29 | 2019-2025 | Idosetr, Idose, Radius |
| Oyster Point Pharma, INC. | $286.03 | 2022-2025 | Tyrvaya |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $270.15 | 2019-2021 | |
| Bausch & Lomb Americas INC. | $258.84 | 2023-2025 | Scoutpro Osmolarity System, Vyzulta, Xiidra |
| Apellis Pharmaceuticals, INC. | $255.49 | 2023-2025 | Syfovre |
| Johnson & Johnson Surgical Vision, INC. | $228.10 | 2024-2025 | Tecnis Simplicity, Veritas Vision System |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Baxter Healthcare | $116.84 | 2023 | Hillrom - Retinavue 700 Imager |
| Biotissue Holdings INC. | $99.36 | 2020-2022 | |
| Thea Pharma INC. | $94.50 | 2023-2025 | Iyuzeh |
| Mallinckrodt Hospital Products INC. | $77.68 | 2024 | Acthar |
| Astellas Pharma US INC | $72.86 | 2025 | Izervay |
| Harrow Eye, LLC | $51.22 | 2025 | Vevye, Natacyn, Verkazia |
| Dompe US, INC. | $39.74 | 2021-2023 | Oxervate |
| Kala Pharmaceuticals, INC. | $33.58 | 2019-2022 | |
| Horizon Therapeutics Plc | $32.28 | 2022-2023 | Tepezza |
| Sight Sciences, INC. | $28.80 | 2024 | Omni Surgical System |
| Ocular Therapeutix, INC. | $22.74 | 2020 | |
| Tarsus Pharmaceuticals, INC. | $21.86 | 2025 | Xdemvy |
| Amgen INC. | $20.94 | 2025 | Tepezza |
| Eagle Pharmaceuticals, INC. | $20.37 | 2024 | |
| Omeros Corporation | $17.03 | 2019 | |
| Ivantis, INC | $15.27 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gabriel Jacob listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.